ArticleFrontiers in oncology2026
Incidence of peritoneal carcinomatosis after perioperative FLOT chemotherapy in gastric cancer. single-center analysis in Kazakhstan.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peritoneal carcinomatosis (PC) significantly impacts prognosis in gastric cancer, limiting survival despite perioperative chemotherapy advancements. The FLOT regimen (5-fluorouracil, leucovorin, oxaliplatin, docetaxel) has become standard for resectable gastric cancer, yet real-world data on PC incidence and clinical impact of PC following FLOT-based treatment, particularly in Central Asia, are limited. This study aimed to evaluate the incidence and clinical implications of PC in a real-world cohort managed with a FLOT-based perioperative strategy in Kazakhstan. Methods: This retrospective cohort study included 74 with gastric cancer treated at the National Research Oncology Center, Kazakhstan (2020-2024). Patients were planned for perioperative FLOT-based systemic therapy followed by curative-intent surgery, with treatment adaptations reflecting routine clinical practice. Outcomes analyzed were overall survival (OS), relapse-free survival (RFS), and carcinomatosis-free survival (CFS), along with treatment response and patterns of recurrence. Results: The cohort was predominantly male (71.6%), with mean age 57.4 years. Most tumors (79.7%) were stage III at diagnosis. One- and two-year OS rates were 87.4% and 70.5%, respectively. RFS rates were 72.0% at one year, decreasing to 53.6% at two years. PC occurred in 50% of relapses, representing the most common recurrence pattern, with median post-progression survival of only 73.5 days. Carcinomatosis-free survival at one and two years was 87.8% and 77.9%, respectively. Prognostic analyses were exploratory due to limited event numbers. Clinical stage was not associated with carcinomatosis-free survival, whereas poorer tumor regression and signet-ring cell histology showed descriptively worse recurrence-free outcomes. Conclusions: Peritoneal carcinomatosis remains a significant challenge following perioperative FLOT chemotherapy in patients with gastric cancer in Kazakhstan, adversely influencing survival outcomes. These findings underscore the necessity for incorporating advanced diagnostic techniques, including peritoneal cytology and improved imaging methods, to enhance early detection and accurate staging. Further prospective studies are warranted to validate these results and develop tailored therapeutic strategies specific to regional healthcare settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.